Get the Daily Brief
Latest Biotech News
Takeda inks multiyear pact with Iambic — AI for small molecules
Takeda signed a multiyear discovery and R&D pact with Iambic to apply the biotech’s generative AI platform to small‑molecule programs across oncology, gastrointestinal and inflammation targets....
AI drug design draws capital: Galux and QuantX close big rounds
Two AI‑focused biotech financings closed this week as investors back algorithmic protein and immunology discovery. Seoul‑based Galux raised $29 million in a Series B to scale its AI‑driven...
Regulator and originator push back on copycat semaglutide
Regulatory and legal pressure intensified after Hims & Hers announced a compounded oral semaglutide product. FDA commissioner Marty Makary publicly pledged swift action against mass‑marketed,...
FDA updates Yescarta label — primary CNS lymphoma allowed
The FDA approved a labeling update for axicabtagene ciloleucel (Yescarta), removing the prior contraindication for treating primary CNS lymphoma after data and regulatory review. The change...
Rezpeg maintains responses at one year — Nektar posts durable data
Nektar Therapeutics reported one‑year maintenance data showing that monthly and quarterly dosing of rezpeg preserved stringent skin‑lesion improvements in 71% and 83% of patients with...
British Journal of Cancer retracts circular‑RNA gastric cancer paper
The British Journal of Cancer issued a formal retraction of a study examining Circular RNA 0000096 in gastric cancer after identifying issues that undermined the paper’s findings. The notice...
Lilly buys Orna: $2.4B bet on in‑vivo CAR‑T
Eli Lilly has agreed to acquire Orna Therapeutics in a deal valuing the company at up to $2.4 billion, buying into Orna’s circular RNA platform and an in‑vivo CAR‑T candidate aimed at B...
FDA rejects Regenxbio’s gene therapy: regulator flags trial design
The FDA issued a complete response rejecting Regenxbio’s RGX‑121 gene therapy for Hunter syndrome, citing concerns about patient‑population definition, use of a natural‑history control arm and...
Generate files IPO: AI‑designed antibody advances to Phase III
Generate Biomedicines filed for an IPO days after dosing the first patient in Phase III for its lead AI‑designed antibody GB‑0895, targeting thymic stromal lymphopoietin (TSLP) in severe asthma....
Takeda inks multiyear pact with Iambic – AI for small‑molecule discovery
Takeda signed a multiyear discovery and technology collaboration with Iambic Therapeutics to deploy Iambic’s generative AI tools across small‑molecule programs in oncology, GI and inflammation....
QuantX raises $85M Series B: Big‑pharma VC backs AI immunology push
QuantX Biosciences closed an $85 million Series B led by Lilly and Sanofi Ventures to advance an immunology pipeline developed across China and the U.S. The round supports QuantX’s AI‑driven...
Medable launches Agentic AI: PIs get help with clinical outcome review
Medable launched an Agentic AI product designed to assist principal investigators in assessing electronic clinical outcome assessment (eCOA) data, automating reconciliation and highlighting items...
Shingles shot linked to lower dementia risk: observational analysis
A study published in Nature Communications reports an association between receipt of the recombinant zoster vaccine (RZV) and reduced risk of developing dementia. Researchers analyzed population...
Engineered immune cells cut toxic brain proteins: preclinical advance
Researchers at Washington University School of Medicine and the Weizmann Institute reported engineered immune cells that target and reduce toxic brain proteins linked to neurodegeneration. Using...
Histone lactylation fuels immune escape in pancreatic cancer
A Nature Communications paper from Zhang, Ma, Wan and colleagues identifies histone lactylation as an epigenetic driver of immune evasion in pancreatic ductal adenocarcinoma. The work shows...
IRB Barcelona opens Spain’s first spatial omics platform — national scale hub
IRB Barcelona launched Spain’s first fully integrated Spatial Omics Platform to provide high‑throughput spatial transcriptomics and proteomics for biomedical research. The platform consolidates...
Lilly buys Orna for $2.4B — stakes a claim in in vivo CAR‑T
Eli Lilly agreed to acquire Orna Therapeutics for up to $2.4 billion to secure an in vivo CAR‑T platform and accelerate entry into genetic medicine. Orna’s circular RNA plus lipid nanoparticle...
FDA rejects Regenxbio gene therapy — Hunter syndrome bid denied
The U.S. Food and Drug Administration issued a complete response letter rejecting Regenxbio’s RGX‑121 for mucopolysaccharidosis type II (Hunter syndrome). The agency flagged concerns about trial...
Novo Nordisk sues Hims — FDA warns against copycat Wegovy pills
Novo Nordisk filed patent litigation against telehealth firm Hims & Hers over an allegedly infringing semaglutide pill and is seeking substantial damages. The complaint centers on Hims’ pill...
Takeda taps Iambic — another pharma AI drug‑discovery tie‑up
Takeda signed a multiyear R&D collaboration with AI firm Iambic to accelerate small‑molecule discovery across oncology, gastrointestinal and inflammation targets. The deal reflects Takeda’s...